Literature DB >> 27765944

Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

V Némethová1, F Rázga1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27765944     DOI： 10.1038/leu.2016.266

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Authors:  L N Eadie; P Dang; V A Saunders; D T Yeung; M P Osborn; A P Grigg; T P Hughes; D L White
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

2.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

Authors:  Stephane Picard; Karine Titier; Gabriel Etienne; Emmanuelle Teilhet; Dominique Ducint; Marie-Agnes Bernard; Regis Lassalle; Gerald Marit; Josy Reiffers; Bernard Begaud; Nicholas Moore; Mathieu Molimard; Francois-Xavier Mahon
Journal:  Blood       Date:  2006-12-27       Impact factor: 22.113

3.  Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.

Authors:  Deborah L White; Phuong Dang; Jane Engler; Amity Frede; Stephanie Zrim; Michael Osborn; Verity A Saunders; Paul W Manley; Timothy P Hughes
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

4.  Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

Authors:  Zdenek Racil; Filip Razga; Katerina Machova Polakova; Lucie Buresova; Vaclava Polivkova; Dana Dvorakova; Daniela Zackova; Hana Klamova; Petr Cetkovsky; Jiri Mayer
Journal:  Leuk Lymphoma       Date:  2010-12-06

5.  The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.

Authors:  Filip Razga; Zdenek Racil; Katerina Machova Polakova; Lucie Buresova; Hana Klamova; Daniela Zackova; Dana Dvorakova; Vaclava Polivkova; Petr Cetkovsky; Jiri Mayer
Journal:  Int J Hematol       Date:  2011-09-08       Impact factor: 2.490

6.  No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.

Authors:  Zdenek Racil; Filip Razga; Hana Klamova; Jaroslava Voglova; Petra Belohlavkova; Ludmila Malaskova; David Potesil; Jan Muzik; Daniela Zackova; Katerina Machova Polakova; Zbynek Zdrahal; Jana Malakova; Jiri Suttnar; Jan Dyr; Jiri Mayer
Journal:  Hematol Oncol       Date:  2013-08-20       Impact factor: 5.271

7.  Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.

Authors:  L Wang; A Giannoudis; S Lane; P Williamson; M Pirmohamed; R E Clark
Journal:  Clin Pharmacol Ther       Date:  2007-06-13       Impact factor: 6.875

8.  The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.

Authors:  Zdenek Racil; Filip Razga; Lucie Buresova; Tomas Jurcek; Dana Dvorakova; Daniela Zackova; Shira Timilsina; Petr Cetkovsky; Jiri Mayer
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047
  8 in total
  4 in total

Review 1.  Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

Authors:  Aritro Nath; Jacqueline Wang; R Stephanie Huang
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

2.  Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation.

Authors:  Lin-Hai Yan; Zhi-Ning Chen; Chun-Jun Li; Jia Chen; Yu-Zhou Qin; Jian-Si Chen; Wei-Zhong Tang
Journal:  J Cancer       Date:  2018-10-05       Impact factor: 4.207

3.  A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking.

Authors:  Onat Kadioglu; Thomas Efferth
Journal:  Cells       Date:  2019-10-21       Impact factor: 6.600

4.  Regulation of ATP-binding cassette subfamily B member 1 by Snail contributes to chemoresistance in colorectal cancer.

Authors:  Hao Wang; Ji-Min Li; Wei Wei; Rui Yang; Dong Chen; Xiao-Dong Ma; Guan-Min Jiang; Bao-Long Wang
Journal:  Cancer Sci       Date:  2019-12-18       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.